50456-78-5

Basic information

• Product Name: 2-hydroxydibenzo[b,e]oxepin-11(6H)-one
• Synonyms: 2-hydroxydibenzo[b,e]oxepin-11(6H)-one
• CAS NO: 50456-78-5
• Molecular Formula: C₁₄H₁₀O₃
• Molecular Weight: 226.2274
• Mol File: 50456-78-5.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Storage Temp.: Refrigerator
• Solubility: DMF; DMSO; Ethyl Acetate; Methanol
• CAS DataBase Reference: 2-hydroxydibenzo[b,e]oxepin-11(6H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-hydroxydibenzo[b,e]oxepin-11(6H)-one(50456-78-5)
• EPA Substance Registry System: 2-hydroxydibenzo[b,e]oxepin-11(6H)-one(50456-78-5)

Safety Data

• Hazardous Substances Data: 50456-78-5(Hazardous Substances Data)

Usage

Description

2-Hydroxydibenzo[b,e]oxepin-11(6H)-one is a chemical compound that serves as an intermediate in the synthesis of various pharmaceuticals. It is characterized by its unique structure, which includes a dibenzo[b,e]oxepin-11(6H)-one core with a hydroxyl group at the 2-position. 2-hydroxydibenzo[b,e]oxepin-11(6H)-one plays a crucial role in the production of specific drugs, making it an essential component in the pharmaceutical industry.

Uses

Used in Pharmaceutical Industry:
2-Hydroxydibenzo[b,e]oxepin-11(6H)-one is used as a key intermediate in the synthesis of (E)-2-Hydroxy Doxepin (H941785), which is a metabolite of Doxepin (D550000). Doxepin is a tricyclic antidepressant medication that is used to treat various mental health conditions, such as depression and anxiety disorders. The synthesis of (E)-2-Hydroxy Doxepin through the use of 2-Hydroxydibenzo[b,e]oxepin-11(6H)-one allows for the development of new therapeutic agents and the enhancement of existing treatments.

Upstream product

• 1122-95-8 sodium 4-methoxyphenolate 
• 23560-68-1 2-<(4-Methoxyphenyl)oxymethyl>benzoic acid 
• 87-41-2 2-benzofuran-1(3H)-one 
• 23560-67-0 2-methoxy-6,11-dihydrodibenz[b,e]oxepin-11-one 
• 872041-16-2 (2-bromomethylphenyl)-(2,5-dihydroxyphenyl)methanone 

Downstream Products

• 139305-56-9 (E)-1-(2-Ethoxy-6,11-dihydrodibenzoxepin-11-yl)-4-(3-phenyl-2-propenyl)piperazine 
• 114312-26-4 (E)-1-(2-Hydroxy-6,11-dihydrodibenzoxepin-11-yl)-4-(3-phenyl-2-propenyl)piperazine 
• 139305-59-2 (E)-1-(2-Benzyloxy-6,11-dihydrodibenzoxepin-11-yl)-4-(3-phenyl-2-propenyl)piperazine difumarate 
• 114312-46-8 (E)-1-(2-tert-Butyldimethylsilyloxy-6,11-dihydrodibenzoxepin-11-yl)-4-(3-phenyl-2-propenyl)piperazine dimaleate 
• 139305-61-6 (E)-1-(2-Methoxymethyloxy-6,11-dihydrodibenzoxepin-11-yl)-4-(3-phenyl-2-propenyl)piperazine fumarate 
• 139305-55-8 (E)-1-(2-Acetoxy-6,11-dihydrodibenzoxepin-11-yl)-4-(3-phenyl-2-propenyl)piperazine 

Relevant articles and documents

Topical formulations for treating allergic diseases

Methods for topically treating allergic diseases of the eye, ear or nose using tricyclic compounds are disclosed.

Synthesis and biological activity of 11-[4-(cinnamyl)-1-piperazinyl]-6,11-dihydrodibenz[b,e]oxepin derivatives, potential agents for the treatment of cerebrovascular disorders

A series of 11-[4-(cinnamyl)-1-piperazinyl]-6,11-dihydrodibenz[b,e]oxepins and related compounds were synthesized and evaluated for their protective activities against complete ischemia, normobaric hypoxia, lipidperoxidation and convulsion. Structure-activity relationship studies of this series led to the finding of (E)-1-(3-fluoro-6,11-dihydrodibenz[b,e]oxepin-11-yl)-4-(3-phenyl-2-prop enyl)piperazine dimaleate (50), AJ-3941 with the most appropriate property for combined pharmacological activities. Compound 50 also shows an inhibitory effect against cerebral edema as well when orally given to rats.